Latest Anthracyclines Stories
PRINCETON, N.J., April 12 /PRNewswire/ -- Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlexÂ® technology platform (U.S.
COLUMBIA, Md., March 18 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that an abstract about the Phase I/II trial of ThermoDoxÂ® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting.
COLUMBIA, Md., Feb. 17 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009.
COLUMBIA, Md., Feb.
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.
PRINCETON, N.J., Jan. 7 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S.
ROCKAWAY, N.J., Dec.
NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al.
PRINCETON, N.J., Dec.
Going smaller could bring better results, especially when it comes to cancer-fighting drugs.
- A poem in which the author retracts something said in an earlier poem.